Palbociclib(Ibrance)

On February 3, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to palbociclib, a prescription drug targeting CDK4/6 kinases, for marketing. Use must be strictly under the guidance of a medical professional.

Target of Action

CDK4/6 kinase

Dosage and Administration

Route and frequency of administration of Palbociclib: Oral, once daily.

The dosage of Palbociclib should be adjusted based on the patient's actual condition. Please consult your doctor and follow their instructions.

Recommended reading: Dosage and administration of Palbociclib

Side Effects

Common side effects: Neutropenia, infections, leukopenia, etc.

Serious side effects: Interstitial lung disease (ILD), pneumonia, etc.

Reference article: Side effects of Palbociclib

Use in Special Populations

Pregnancy: Palbociclib may cause fetal harm. Women of childbearing potential are advised to use effective contraception during treatment with Palbociclib and for at least 3 weeks after the last dose.

Breastfeeding: Due to the potential for serious adverse reactions in breastfed infants, women are advised not to breastfeed during treatment with Palbociclib and for 3 weeks after the last dose.

Daily Precautions

1. Emphasize that Palbociclib should be taken with food. Avoid consuming grapefruit or grapefruit juice during treatment.

2. For premenopausal or perimenopausal women, emphasize the importance of concomitant treatment with a luteinizing hormone-releasing hormone (LHRH) agonist.

3. Instruct patients to swallow capsules or tablets whole, without chewing, crushing, or opening/breaking them.

FDA，2022.12